Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals (Nasdaq: SNDX) announced the granting of inducement awards to four new employees on November 1, 2024.

Rhea-AI Summary

Syndax Pharmaceuticals (Nasdaq: SNDX) announced the granting of inducement awards to four new employees on November 1, 2024. The awards consist of stock options to purchase up to 78,700 shares of common stock under the Company's 2023 Inducement Plan. The options will vest over four years, with 25% vesting after one year and the remaining vesting monthly over the following 36 months, contingent on continued employment with Syndax.

Argus Publication session

-0.21% session move Open Argus

Details

News Market Reaction – SNDX

In the trading session that priced this news, SNDX declined 0.21%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Nov. 1, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on November 1, 2024 the Company granted inducement awards to purchase up to 78,700 shares of common stock to four new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.

About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a selective menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X (formerly Twitter) and LinkedIn.

Syndax Contact

Sharon Klahre 
Syndax Pharmaceuticals, Inc. 
sklahre@syndax.com 
Tel 781.684.9827

View original content:https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302293985.html

SOURCE Syndax Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares were granted in Syndax Pharmaceuticals (SNDX) inducement awards on November 1, 2024?

Syndax Pharmaceuticals granted inducement awards to purchase up to 78,700 shares of common stock on November 1, 2024.

What is the vesting schedule for SNDX's November 2024 inducement stock options?

The stock options vest over four years, with 25% vesting after one year and 1/48th vesting monthly over the following 36 months, subject to continued employment.

How many employees received SNDX inducement grants in November 2024?

Four new employees received inducement grants from Syndax Pharmaceuticals.